Drug Profile
Research programme: overactive bladder therapies - Safetek
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Safetek International
- Class
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in USA
- 12 May 2006 Preclinical trials in Overactive bladder in USA (unspecified route)